Court Opinion

ID: 2678783
Source: CourtListenerOpinion
Date Created: 2014-06-17 21:00:35.793546+00
Date Added: 2024-06-11T13:10:54.109100
License: Public Domain

FILED
                           NOT FOR PUBLICATION                                  JUN 17 2014

                                                                          MOLLY C. DWYER, CLERK
                    UNITED STATES COURT OF APPEALS                          U.S. COURT OF APPEALS

                            FOR THE NINTH CIRCUIT

MARY KAREN MORETTI,                              No. 12-16334

              Plaintiff - Appellant,             D.C. No. 2:08-cv-00396-JCM-
                                                 CWH
  v.

WYETH, INC.; et al.,                             MEMORANDUM*

              Defendants - Appellees.

                    Appeal from the United States District Court
                             for the District of Nevada
                     James C. Mahan, District Judge, Presiding

                       Argued and Submitted May 15, 2014
                            San Francisco, California

Before: McKEOWN and M. SMITH, Circuit Judges, and BOLTON, District
Judge.**

       Mary Moretti appeals from the district court’s dismissal of her claims

against defendant PLIVA, Inc., and a grant of summary judgment to defendants

        *
             This disposition is not appropriate for publication and is not precedent
except as provided by 9th Cir. R. 36-3.
       **
             The Honorable Susan R. Bolton, United States District Judge for the
District of Arizona, sitting by designation.
Wyeth, Inc. and Schwartz Pharma, Inc. (together, Brand Defendants). We have

jurisdiction under 20 U.S.C. § 1291, and we affirm.

I. The Brand Defendants

      Before the district court, Moretti conceded entry of summary judgment on

all of her claims against the Brand Defendants except for her claims based on:

misrepresentation by omission (Count 5); constructive fraud (Count 6); negligent

misrepresentation (Count 12); and fraud by concealment (Count 13). The district

court properly concluded that Nevada law does not recognize Moretti’s claims.

      Under Nevada law, a misrepresentation by omission is actionable only if the

defendant was under a duty to disclose the relevant information. Dow Chem. Co.

v. Mahlum, 114 Nev. 1468, 1486 (1998). “The duty to disclose requires, at a

minimum, some form of relationship between the parties.” Id. at 1487. Mahlum

explicitly rejected concealment claims against Dow Chemical, stating that: “Dow

Chemical had no duty to disclose to the Mahlums any superior knowledge it may

have had regarding the safety of silicone products, however, because it was not

directly involved in the transaction from which this lawsuit arose, or any other

transaction with the Mahlums.” Id.

      Moretti argues that the Mahlum court’s discussion regarding liability for

negligent performance of an undertaking provides a duty of disclosure here.

                                          2
Mahlum, however, held that a jury could find that Dow Chemical had taken upon

itself responsibility for testing silicone used in products manufactured by Dow

Corning—a subsidiary that Dow Chemical formed for that purpose and over which

it retained significant control—and that a jury could conclude that Dow Chemical

had negligently performed that duty “by failing to either conduct further tests to

determine the long-term effects of silicones in the human body or at least advise

Dow Corning on the need for such studies.” Id. at 1498.

      Here, unlike in Mahlum, the Complaint does not allege that the Brand

Defendants undertook “to render testing, advisory, laboratory and personnel

services for the purpose of promoting the safety of [PLIVA’s Metoclopramide] in

order to benefit third persons and had significant control over [its] development,”

or that the Brand Defendant’s negligently performed such work. Rather, the only

question before the district court was whether Nevada law recognized a claim

against the Brand Defendants for misreprepresentation. The district court properly

held that Nevada does not recognize such a claim in the absence of “some form of

relationship between the parties.” Id. at 1487.

II. PLIVA

      After the Supreme Court’s decision in PLIVA, Inc. v. Mensing, 131 S.Ct

2567 (2011), the test for preemption in the generic drug field inquires whether a

                                         3
manufacturer of generic drugs can independently comply with duties imposed on it

by state tort law without violating federal laws regulating the manufacture and

advertising of prescription drugs. Mensing, 131 S.Ct. at 2577–2581. Mensing and

Mutual Pharmaceutical Co., Inc. v. Bartlett, 133 S.Ct. 2466 (2013), make clear

that tort claims based on a generic manufacturer’s failure to unilaterally strengthen

warning claims are preempted by the federal requirement that generic labels

display exactly the same information as the federally approved brand-name label,

and that tort claims based on a generic manufacturer’s failure to change the

chemical composition of the drug are preempted by the federal duty of sameness.

Mensing also clarifies that claims based on a generic’s failure to report incident

information to the FDA are preempted because the generic manufacturer could not

independently comply with its state-law duties—strengthening the warning label in

line with new evidence—because any label change was dependant on the FDA’s

discretionary action. Mensing, 131 S.Ct. at 2581. Finally, Bartlett bars claims

based on a manufacturer’s failure to exit the market for a particular drug. Bartlett,

133 S.Ct. at 2477.

      The Complaint in this case is focused on “[defendants’] dissemination of

inaccurate, misleading, materially incomplete, false, and otherwise inadequate

information concerning the potential effects of exposure to [metoclopramide].”

                                          4
As the Complaint itself acknowledges, “[t]his case involves [defendants’] failure to

warn doctors and patients of information within its knowledge or possession . . . ,

which indicated [that metoclopramide], when taken for an extended period of time,

caused serious, permanent, and debilitating side effects.” Moretti has not proposed

any action by which PLIVA could comply with the state-law obligations asserted

in the Complaint without violating federal law. Although claims based on

PLIVA’s failure to update its label in 2004 to match the newly strengthened brand-

name label might meet such a test, Moretti conceded at oral argument that she was

no longer taking metoclopramide at the time of the label change. Accordingly, the

district court properly dismissed all of Moretti’s claims against PLIVA as

preempted by federal law.

      AFFIRMED.

                                         5